Lipocine (NASDAQ:LPCN) Trading Up 2.1%
Lipocine Inc (NASDAQ:LPCN)’s stock price was up 2.1% on Monday . The company traded as high as $2.35 and last traded at $2.39, approximately 3,984 shares were traded during trading. A decline of 97% from the average daily volume of 120,444 shares. The stock had previously closed at $2.34.
Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Lipocine in a research report on Wednesday, May 15th.
The company has a current ratio of 4.42, a quick ratio of 4.42 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $59.62 million, a P/E ratio of -4.71 and a beta of 1.02. The firm has a 50-day moving average of $1.93 and a two-hundred day moving average of $1.87.
Hedge funds have recently made changes to their positions in the stock. Mercer Global Advisors Inc. ADV bought a new stake in shares of Lipocine during the 1st quarter worth $256,000. Spark Investment Management LLC bought a new stake in shares of Lipocine during the 1st quarter worth $118,000. FNY Investment Advisers LLC bought a new stake in shares of Lipocine during the 2nd quarter worth $27,000. Vanguard Group Inc. lifted its position in shares of Lipocine by 15.7% during the 2nd quarter. Vanguard Group Inc. now owns 555,868 shares of the specialty pharmaceutical company’s stock worth $1,084,000 after buying an additional 75,245 shares during the last quarter. Finally, BlackRock Inc. lifted its position in shares of Lipocine by 17.2% during the 2nd quarter. BlackRock Inc. now owns 364,196 shares of the specialty pharmaceutical company’s stock worth $710,000 after buying an additional 53,535 shares during the last quarter. Institutional investors and hedge funds own 12.84% of the company’s stock.
About Lipocine (NASDAQ:LPCN)
Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.
Featured Story: Death Cross
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.